Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point - Exact Sciences ( NASDAQ:EXAS )

a week ago

On Tuesday, Exact Sciences Corp. EXAS reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst consensus loss estimate of $0.20. The reported quarterly sales of $708.66 million missed the consensus estimate of $717.66 million.

Ticker	Sentiment	Impact
EXAS	Somewhat Bearish	40 %